A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
NCT01551056
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
91
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
AC-170 0.24%
DRUG:
AC-170 0%
Sponsor
Aciex Therapeutics, Inc.